Dr. Eric Vigneault
Claim this profileCHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Area of expertise
Prostate Cancer
Eric Vigneault has run 7 trials for Prostate Cancer. Some of their research focus areas include:
Prostate Adenocarcinoma
Eric Vigneault has run 3 trials for Prostate Adenocarcinoma.
Affiliated Hospitals
CHU De Quebec-L'Hotel-Dieu De Quebec (HDQ)
Hotel-Dieu De Quebec
Clinical Trials Eric Vigneault is currently running
Shorter vs Usual Radiation Therapy
for Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting
2 awards
Phase 3
10 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting
2 awards
Phase 3
1 criteria
More about Eric Vigneault
Clinical Trial Related
5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Eric Vigneault has experience with
- Bicalutamide
- Degarelix
- Histrelin
- Leuprolide
- Triptorelin
- Goserelin
Breakdown of trials Eric Vigneault has run
Prostate Cancer
Prostate Adenocarcinoma
Metabolic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eric Vigneault specialize in?
Eric Vigneault focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved metastatic patients, or patients who are localized.
Is Eric Vigneault currently recruiting for clinical trials?
Yes, Eric Vigneault is currently recruiting for 3 clinical trials in Quebec City Quebec. If you're interested in participating, you should apply.
Are there any treatments that Eric Vigneault has studied deeply?
Yes, Eric Vigneault has studied treatments such as Bicalutamide, Degarelix, Histrelin.
What is the best way to schedule an appointment with Eric Vigneault?
Apply for one of the trials that Eric Vigneault is conducting.
What is the office address of Eric Vigneault?
The office of Eric Vigneault is located at: CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City, Quebec G1R 2J6 Canada. This is the address for their practice at the CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.